Table 1.
Basic characteristics for eight eligible studies.
| First author | Year | Arm | Placebo/Blinding | No. | Accrual time | mOS (y) | Median age (y) | Sex (M/F) | PS ECOG | Mechanism of anti-angiogenesis | Treatment regimen | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goncalves 13 | 2012 | G+Sorafenib | Y/Y | 52 | Dec 2006-Sep 2009 | 3.8 | 61 (42-85) | 30/22 | 0-1:42; 2:5 | VEGFR inhibitor | Gem 1,000mg/m2, weekly for 1st cycle (7 weeks), then weekly 3 every 4 weeks for cycle 2 and 3 | |
| G | 52 | 5.7 | 64 (40-82) | 32/20 | 0-1:48; 2:3 | Sorafenib or placebo 200mg twice daily | ||||||
| Kindler 14 | 2011 | G+Axitinib | Y/Y | 314 | Jul 2007-Oct 2008 | 8.5 | 61 (34-84) | 191/123 | 0-1:309 | VEGFR inhibitor | Gem 1,000mg/m2, weekly 3 every 4 weeks | |
| G | 316 | 8.3 | 62 (35-89) | 188/128 | 0-1:312 | Axitinib or placebo 5mg twice daily | ||||||
| Yamane 15 | 2015 | G+Elpamotide | Y/Y | 100 | Jan 2009-Jan 2010 | NA | 63.5 (38-80) | 62/38 | 0-1:100 | VEGFR inhibitor | Gem 1,000mg/m2, weekly 3 every 4 weeks | |
| G | 53 | NA | 65 (36-80) | 31/22 | 0-1:53 | elpamotide 2.0mg/ml/body or placebo 1.0ml/body | ||||||
| Rouguer 16 | 2013 | G+Aflibercept | Y/Y | 271 | Dec 2007-Sep 2009 | 6.5 | 62 (34-88) | 160/11 | 0-1:254; 2:17 | soluble VEGFR inhibitor | Gem 1,000mg/m2, weekly for 1st cycle (4 weeks), then weekly 3 every 4 weeks | |
| G | 275 | 7.8 | 61 (34-86) | 157/118 | 0-1:256; 2:19 | 4mg/kg once every 2 weeks or placebo | ||||||
| Kindler 17 | 2010 | G+Bev | NA/NA | 302 | Jun 2004-Apr 2006 | 5.8 | 63.7 (26-88) | 175/127 | 0-1:266; 2:36 | VEGF inhibitor | Gem 1,000mg/m2, weekly 3 every 4 weeks | |
| G | 300 | 5.9 | 65 (35-83) | 153/147 | 0-1:270; 2:30 | BEV 10mg/kg once every 2 weeks or placebo | ||||||
| Moore 11 | 2007 | G+Erlotinib | Y/Y | 285 | Oct 2001-Jan 2003 | 6.24 | 63.7 (37.7-84.4) | 136/149 | 0-1:230; 2:54 | EGFR inhibitor | Gem 1,000mg/m2, weekly for 1st cycle (7 weeks), then weekly 3 every 4 weeks | |
| G | 284 | 5.91 | 64 (36.1-92.4) | 162/22 | 0-1:232; 2:52 | Erlotinib or placebo 100 or 150mg/d | ||||||
| Philip 18 | 2010 | G+Cetuximab | NA/NA | 372 | Jan 2004-Apr 2006 | 6.3 | 63.7 | 190/182 | 0-1:324; 2:48 | EGFR inhibitor | Gem 1,000mg/m2, weekly for 1st cycle (7 weeks), then weekly 3 every 4 weeks | |
| G | 371 | 5.9 | 64.3 | 200/171 | 0-1:323; 2:48 | Cetuximab 400mg/m2 on week 1, then weekly 250mg/m2 | ||||||
| Bramhall 19 | 2002 | G+Marimastat | Y/Y | 120 | Sep 1997-Apr 1998 | 165d | 62 (32-83) | 69/51 | KPS | MMPs inhibitor | Gem 1,000mg/m2 | |
| G | 119 | 164d | 62 (37-85) | 71/48 | KPS | Marimastat 10mg twice daily or placebo |
*M, male; F, female; No., patients number; mOS, median Overall survival; NA, not available; Y, Yes; y, year; G or Gem, gemcitabine; PS, performance status.